Drug Profile
U3 1784
Alternative Names: U3-1784Latest Information Update: 20 Oct 2017
Price :
$50
*
At a glance
- Originator U3 Pharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cancer; Solid tumours
Most Recent Events
- 09 Oct 2017 Daiichi Sankyo terminates a phase I trial in Solid tumours in United Kingdom due to business reasons (NCT02690350)
- 01 May 2017 Discontinued - Phase-I for Liver cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom (IV) (Daiichi Sankyo pipeline, May 2017)
- 01 May 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in United Kingdom (IV) (Daiichi Sankyo pipeline, May 2017)